Effect of Treatment BI 1744 CL (5 and 10 Mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I
This study has been completed.
Sponsor:
Boehringer Ingelheim Pharmaceuticals
Information provided by:
Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01040130
First received: December 28, 2009
Last updated: July 27, 2011
Last verified: July 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To compare the effects of BI 1744 CL versus placebo on exercise tolerance after 6 weeks of treatment in patients with Chronic Obstructive Pulmonary Disease
| Condition | Intervention | Phase |
|---|---|---|
|
Pulmonary Disease, Chronic Obstructive |
Drug: Olodaterol (BI 1744) Drug: Placebo Drug: Olodaterol (BI 1744) Placebo |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Randomised, Double-blind, Placebo-controlled, 3-way Cross-over Study to Determine the Effect of Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 µg] and 10 µg [2 Actuations of 5 µg]) Delivered by the Respimat® Inhaler on Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease |
Resource links provided by NLM:
MedlinePlus related topics:
COPD (Chronic Obstructive Pulmonary Disease)
Exercise and Physical Fitness
U.S. FDA Resources
Further study details as provided by Boehringer Ingelheim Pharmaceuticals:
Primary Outcome Measures:
- Endurance time during constant work rate cycle ergometry to symptom limitation at 75% of Maximum Work Capacity after 6 weeks of treatment (Day 43). [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- FRC, IC, TLC [ Time Frame: trough and 1 hr post-dose ] [ Designated as safety issue: No ]
- FEV1, FVC, PEF [ Time Frame: trough and 1 hr post-dose ] [ Designated as safety issue: No ]
- Inspiratory capacity (IC) during constant work rate cycle ergometry to symptom limitation at 75% Wcap [ Time Frame: pre-exercise, every 2 minutes during exercise, end exercise ] [ Designated as safety issue: No ]
- Intensity of breathing discomfort during constant work rate cycle ergometry to symptom limitation at 75% Wcap [ Time Frame: pre-exercise, every 2 minutes during exercise, end exercise ] [ Designated as safety issue: No ]
- Intensity of leg discomfort during constant work rate cycle ergometry to symptom limitation at 75% Wcap [ Time Frame: pre-exercise, every 2 minutes during exercise, end exercise ] [ Designated as safety issue: No ]
- Locus of symptom limitation (breathing discomfort, leg discomfort, breathing and leg discomfort, other) during constant work rate cycle ergometry to symptom limitation at 75% Wcap [ Time Frame: pre-exercise, every 2 minutes during exercise, end exercise ] [ Designated as safety issue: No ]
- SaO2, VO2, VCO2, Ti, Te, VE, VT, breathing frequency (f) during constant work rate cycle ergometry to symptom limitation at 75% Wcap [ Time Frame: pre-exercise, during exercise, end exercise and recovery ] [ Designated as safety issue: No ]
- Pulse rate, blood pressure [ Time Frame: in conjunction with spirometry ] [ Designated as safety issue: Yes ]
- Heart rate, blood pressure [ Time Frame: in conjunction with exercise ] [ Designated as safety issue: Yes ]
- ECG [ Time Frame: at rest and during exercise ] [ Designated as safety issue: Yes ]
- All adverse events (including physical examination) [ Time Frame: throughout trial ] [ Designated as safety issue: Yes ]
- Inspiratory capacity at isotime during constant work rate cycle test to symptom limitation at 75% max work capacity. Intensity of breathing discomfort at isotime during constant work rate cycle test to symptom limitation at 75% max work capacity [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
| Enrollment: | 151 |
| Study Start Date: | January 2010 |
| Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Olodaterol (BI 1744) Low
Low dose inhaled orally once daily from the Respimat inhaler
|
Drug: Olodaterol (BI 1744)
Comparison of low and high doses on exercise endurance time in COPD patients
Drug: Olodaterol (BI 1744)
Comparison of low and high dose
Drug: Olodaterol (BI 1744) Placebo
Placebo that represents olodaterol
|
|
Experimental: Olodaterol (BI 1744) High
High dose inhaled orally once daily from the Respimat inhaler
|
Drug: Olodaterol (BI 1744)
Comparison of low and high doses on exercise endurance time in COPD patients
|
|
Placebo Comparator: Placebo
Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler
|
Drug: Placebo
Comparison of low and high dose and placebo on exercise endurance time in COPD patients
|
Eligibility| Ages Eligible for Study: | 40 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria:
- Signed informed consent prior to participation.
- Diagnosis of chronic obstructive pulmonary disease and post-bronchodilator FEV1(Forced Expiratory Volume in 1 sec) <80% of predicted normal and post-bronchodilator FEV1(Forced Expiratory Volume in 1 sec)/FVC of < 70% at Visit 1.
- Male or female between 40 and 75 years of age.
- Current or ex-smokers with smoking history of more than 10-pack years.
- Able to perform technically acceptable pulmonary function tests, multiple exercise tests and able to maintain records.
- Able to inhale medication in a competent manner from a metered-dose inhaler and Respimat inhaler.
Exclusion criteria:
- Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis; all patients with an SGOT >x2 ULN, SGPT >x2 ULN, bilirubin >x2 ULN or creatinine >x2 ULN.
- Patients with a history of asthma and/or total blood eosinophil count of 600 cells/mm3.
- Patients with thyrotoxicosis, paroxysmal tachycardia (>100 beats per minute).
- Patients with a history of myocardial infarction within 1 year of screening visit, unstable or life-threatening cardiac arrhythmia, hospitalization for heart failure within the past year, known active tuberculosis, a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years, life-threatening pulmonary obstruction, cystic fibrosis, clinically evident bronchiectasis, significant alcohol or drug abuse or contraindications to exercise.
- Patients who have undergone thoracotomy with pulmonary resection.
- Patients being treated with oral beta-adrenergics or oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day.
- Patients who regularly use daytime oxygen for more than one hour per day.
- Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit or patients who are currently in a pulmonary rehabilitation program.
- Patients who have a limitation of exercise performance as a result of factors other than fatigue or exertional dyspnea.
- Pregnant or nursing women.
- Women of childbearing potential not using two effective methods of birth control (one barrier and one non-barrier).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01040130
Locations
| Australia, South Australia | |
| 1222.37.6171 Boehringer Ingelheim Investigational Site | |
| Daw Park, South Australia, Australia | |
| Australia, Victoria | |
| 1222.37.6174 Boehringer Ingelheim Investigational Site | |
| Clayton, Victoria, Australia | |
| 1222.37.6173 Boehringer Ingelheim Investigational Site | |
| Heidelberg, Victoria, Australia | |
| 1222.37.6172 Boehringer Ingelheim Investigational Site | |
| Melbourne, Victoria, Australia | |
| Austria | |
| 1222.37.4371 Boehringer Ingelheim Investigational Site | |
| Gänserndorf, Austria | |
| 1222.37.4372 Boehringer Ingelheim Investigational Site | |
| Neumarkt am Wallersee, Austria | |
| Canada, Ontario | |
| 1222.37.1072 Boehringer Ingelheim Investigational Site | |
| Hamilton, Ontario, Canada | |
| Canada, Quebec | |
| 1222.37.1074 Boehringer Ingelheim Investigational Site | |
| Montreal, Quebec, Canada | |
| 1222.37.1073 Boehringer Ingelheim Investigational Site | |
| Ste-Foy, Quebec, Canada | |
| France | |
| 1222.37.33005 Boehringer Ingelheim Investigational Site | |
| Bethune Cedex, France | |
| 1222.37.33002 Boehringer Ingelheim Investigational Site | |
| Montpellier, France | |
| 1222.37.33001 Boehringer Ingelheim Investigational Site | |
| Nîmes, France | |
| 1222.37.33006 Boehringer Ingelheim Investigational Site | |
| Paris, France | |
| 1222.37.33004 Boehringer Ingelheim Investigational Site | |
| Perpignan, France | |
| 1222.37.33003 Boehringer Ingelheim Investigational Site | |
| Strasbourg, France | |
| Germany | |
| 1222.37.4970 Boehringer Ingelheim Investigational Site | |
| Berlin, Germany | |
| 1222.37.4972 Boehringer Ingelheim Investigational Site | |
| Halle, Germany | |
| 1222.37.4973 Boehringer Ingelheim Investigational Site | |
| Magdeburg, Germany | |
| 1222.37.4971 Boehringer Ingelheim Investigational Site | |
| Rüdersdorf, Germany | |
Sponsors and Collaborators
Boehringer Ingelheim Pharmaceuticals
Investigators
| Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim Pharmaceuticals |
More Information
No publications provided
| Responsible Party: | Boehringer Ingelheim, Study Chair, Boehringer Ingelheim |
| ClinicalTrials.gov Identifier: | NCT01040130 History of Changes |
| Other Study ID Numbers: | 1222.37, 2009-014395-21 |
| Study First Received: | December 28, 2009 |
| Last Updated: | July 27, 2011 |
| Health Authority: | Australia: Dept of Health and Ageing Therapeutic Goods Admin Austria: Federal Office for Safety in Health Care Canada: Health Canada France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) Germany: Federal Institute for Drugs and Medical Devices |
Additional relevant MeSH terms:
|
Chronic Disease Lung Diseases Respiration Disorders Pulmonary Disease, Chronic Obstructive |
Lung Diseases, Obstructive Disease Attributes Pathologic Processes Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 23, 2013